Dekang Medical has been selected as the first company to participate in the FDA's Digital Health Device Pilot Program.
Golden Finance, July 23 — Continuous blood glucose monitoring device manufacturer Dexcom Medical has been selected by the U.S. FDA as the first company to participate in the TEMPO digital health device pilot project. The TEMPO project aims to evaluate new digital health technologies that help improve chronic disease management and provide real-world data. Dexcom Medical will implement an AI-driven blood glucose health program, combining data from Dexcom G7 and Stelo devices with contextual health information such as nutrition, physical activity, sleep, and stress, in order to provide more personalized insights for healthcare professionals and eligible users.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sony (SONY.US) to miss the 2027 CES after dissolving joint venture with Honda (HMC.US), shifts focus to entertainment content
Sony Group (SONY.US) will not participate in the 2027 International Consumer Electronics Show (CES), ending its decades-long history of attending this major electronics event in Las Vegas. Instead, the company will shift its focus more towards its entertainment content business.
Intervention risk rises again! After signals from Japan and the US, Japan's top foreign exchange official warns: the market should take this seriously
Jun Azumi stated on Monday that the market should take seriously the "very clear" message about the yen issued last week by Tokyo and Washington. His remarks signal his readiness to take action to curb excessive depreciation of the yen.
Barrick Mining (B.US) reaches collective agreement with Mali gold miners' union, strike threat lifted
Barrick Mining has reached an agreement with the Mali Gold Miners Union, alleviating the threat of a strike.
Crypto prices
More
